Corner Widget
young family goes for a walkyoung family goes for a walk mobile photo

Providing Information
to Keep You Up to Date

Team Blog

Hello, and welcome to the ITF Therapeutics Team Blog. We wanted to connect with people in the DMD community in a way that feels more personal than the usual corporate modes of communication. We will take turns writing about what we think may be helpful or interesting to you as you make your way through life with Duchenne. We will share what we do all day at work, explain new developments and what they may mean in the context of real life, and break down topics that may seem heavily scientific or otherwise difficult to sort through and make sense of.

As much as we want to introduce ourselves and keep you updated about key developments here at ITF Therapeutics, we also want to get to know you better. Your insights have played a central role in advancing our research and our effort to bring a treatment to the community, and with your help we can make sure that we are always improving our ability to support you and meet your needs. In our blog posts we will often ask you for your opinions and questions – and we want to hear from you!

So please consider this blog as a two-way street, a place where we can learn more about each other and keep learning from each other. The more we share insights, the better we will get at making this world a better place for all people affected by DMD.

The ITF Team

ITF in Year Two: 
Where We Are Headed

Matt Trudeau

President of ITF Therapeutics

2/26/25

ITF’s first year of operations was unforgettable. We worked at breakneck speed to design and implement all the structures, processes, systems, and procedures necessary to bring a therapy to market. It has been gratifying to introduce a treatment option to a rare disease community that has been yearning, for far too long, for meaningful interventions.... Read More

2024 Wrap Up

ITF Leadership Team

1/8/25

As we kick off 2025, we wanted to take a moment to reflect on the past year. We all feel a deep sense of gratitude to the Duchenne muscular dystrophy (DMD) community.... Read More

On Building a Mission-Focused Company

Melinda Keegan

Head of US Human Resources

12/13/24

Launching a new medication in the U.S. is no small feat. It requires a diverse team of specialists such as manufacturing experts, regulatory professionals, field representatives who work with physicians and payers, patient advocates who build bridges to the community, and medical teams... Read More

Fraught with Treatment Decisions: How Can We Help?

Dan O'Connell

VP, Head of US Marketing

11/15/24

I can only imagine what it must feel like to be responsible for treatment decisions on behalf of someone who lives with Duchenne muscular dystrophy (DMD). Whether that person is yourself or someone you love, the stakes are unspeakably high... Read More

A Guest in Your Home

Matt Trudeau

President of ITF Therapeutics

11/1/24

We've all had interactions at one point or another with the kind of house guests who aren't welcome – those who impose themselves on the scene with little regard for their hosts, primarily focused on what they can gain from the situation. I firmly believe that that kind of behavior is also bad in business... Read More

FDA Approval Granted, Access Denied – Now What?

Stephanie Trafton

Head of US Value & Access

10/4/24

The United States of America is famous for medical innovation. Our country leads the world in the number of new drugs and medical devices that are given the green light by our government. Unfortunately, this does not mean that every approved new... Read More

What Makes an Expert?

Scott Baver

Vice President, Head of US Medical Affairs

9/23/24

I have been studying neuroscience and working in the field of neuromuscular disease for more than 20 years. I may have the academic degrees and the work experience to qualify as an "expert," but there's no doubt in my mind that the real experts are you... Read More

A Good Day

Caroline Allen

Head, US Patient Advocacy & Communications

7/25/24

In the long path to new treatments for Duchenne, today is a good day. A medicine that is designed to interfere with Duchenne’s relentless progression is now officially available in the United States. While I am feeling positive and hopeful because of this... Read More